These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29324282)

  • 21. Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon.
    Chen W; Kong L; Connelly S; Dendle JM; Liu Y; Wilson IA; Powers ET; Kelly JW
    ACS Chem Biol; 2016 Jul; 11(7):1852-61. PubMed ID: 27128252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.
    Okbazghi SZ; More AS; White DR; Duan S; Shah IS; Joshi SB; Middaugh CR; Volkin DB; Tolbert TJ
    J Pharm Sci; 2016 Feb; 105(2):559-574. PubMed ID: 26869419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization.
    An Y; Zhang Y; Mueller HM; Shameem M; Chen X
    MAbs; 2014; 6(4):879-93. PubMed ID: 24927271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consequences of glycan truncation on Fc structural integrity.
    Buck PM; Kumar S; Singh SK
    MAbs; 2013; 5(6):904-16. PubMed ID: 24492344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-translational modifications differentially affect IgG1 conformation and receptor binding.
    Houde D; Peng Y; Berkowitz SA; Engen JR
    Mol Cell Proteomics; 2010 Aug; 9(8):1716-28. PubMed ID: 20103567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
    Subedi GP; Barb AW
    MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disulfide Modified IgG1: An Investigation of Biophysical Profile and Clinically Relevant Fc Interactions.
    Bahou C; Love EA; Leonard S; Spears RJ; Maruani A; Armour K; Baker JR; Chudasama V
    Bioconjug Chem; 2019 Apr; 30(4):1048-1054. PubMed ID: 30855134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
    Ha S; Ou Y; Vlasak J; Li Y; Wang S; Vo K; Du Y; Mach A; Fang Y; Zhang N
    Glycobiology; 2011 Aug; 21(8):1087-96. PubMed ID: 21470983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying a robust design space for glycosylation during monoclonal antibody production.
    St Amand MM; Hayes J; Radhakrishnan D; Fernandez J; Meyer B; Robinson AS; Ogunnaike BA
    Biotechnol Prog; 2016 Sep; 32(5):1149-1162. PubMed ID: 27273898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-linked glycan structures of the human Fcγ receptors produced in NS0 cells.
    Cosgrave EF; Struwe WB; Hayes JM; Harvey DJ; Wormald MR; Rudd PM
    J Proteome Res; 2013 Aug; 12(8):3721-37. PubMed ID: 23777450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
    Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
    PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry.
    More AS; Toth RT; Okbazghi SZ; Middaugh CR; Joshi SB; Tolbert TJ; Volkin DB; Weis DD
    J Pharm Sci; 2018 Sep; 107(9):2315-2324. PubMed ID: 29751008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass Spectrometry Characterization of Higher Order Structural Changes Associated with the Fc-glycan Structure of the NISTmAb Reference Material, RM 8761.
    Groves K; Cryar A; Cowen S; Ashcroft AE; Quaglia M
    J Am Soc Mass Spectrom; 2020 Mar; 31(3):553-564. PubMed ID: 32008322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
    Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
    MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.
    Giddens JP; Wang LX
    Methods Mol Biol; 2015; 1321():375-87. PubMed ID: 26082235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity.
    Chen CL; Hsu JC; Lin CW; Wang CH; Tsai MH; Wu CY; Wong CH; Ma C
    ACS Chem Biol; 2017 May; 12(5):1335-1345. PubMed ID: 28318221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.